Detalhe da pesquisa
1.
Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study.
Clin Infect Dis
; 77(5): 740-748, 2023 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37288954
2.
Determinants of HIV late presentation among men who have sex with men in Portugal (2014-2019): who's being left behind?
Front Public Health
; 12: 1336845, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500732
3.
Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.
J Antimicrob Chemother
; 68(1): 190-2, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22977160
4.
HIV-1-Transmitted Drug Resistance and Transmission Clusters in Newly Diagnosed Patients in Portugal Between 2014 and 2019.
Front Microbiol
; 13: 823208, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35558119
5.
Two cases of dolutegravir failure with R263K mutation.
AIDS
; 32(17): 2639-2640, 2018 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30379690